Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Efficacy and Safety of SHR-1918 in HoFH
NCT07133815Phase 2Not yet recruiting
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHR-1918 in familial hypercholesterolemia (FH), sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Primary endpoint: Incidence and Severity of Adverse Events at 48 months. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
SHR-1918
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT07133815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07133815.